Hepatology coordination
The first targeted therapies for PBC beyond UDCA, and the first FDA-approved therapy for MASH with moderate-to-advanced fibrosis — coordinated into the hepatology clinic's chain of custody.
Hepatology coordination has expanded with the first FDA-approved therapies specifically for primary biliary cholangitis that goes beyond ursodeoxycholic acid, and the first FDA-approved therapy specifically for metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced fibrosis.
Hepatology therapies we commonly coordinate
- Primary biliary cholangitis — Iqirvo (elafibranor, PPARα/δ dual agonist) for patients with inadequate response to or intolerance of UDCA.
- MASH (formerly NASH) — Rezdiffra (resmetirom, liver-directed THR-β agonist) for noncirrhotic MASH with F2–F3 fibrosis, together with diet and exercise.
- Rare cholestatic paediatric liver disease — IBAT inhibitors and related orphan therapies, coordinated with paediatric hepatology centres.
Coordination posture
The treating hepatologist holds the disease-stage call (fibrosis F-score, UDCA-response classification, biochemical markers) and the therapy selection. We coordinate sourcing, dispensing partner review, and delivery into the hepatology clinic's chain of custody.